1.Clinical study on the prevention of chemotherapy-induced nausea and vomiting using Erchen decoction acupoint application
Wanchun YE ; Lingling JIANG ; Ren YE
Chinese Journal of Primary Medicine and Pharmacy 2025;32(11):1640-1644
Objective:To investigate the clinical effects of Erchen decoction acupoint application on the prevention of chemotherapy-induced nausea and vomiting. Methods:A prospective study was conducted involving 120 patients with solid tumors who visited Wenzhou Central Hospital between January 2022 and July 2023. The patients were randomly divided into an observation group and a control group using a random number table method. Ultimately, 55 patients in the observation group and 51 patients in the control group completed the study (due to dropouts or rescue treatment, 5 patients were excluded from the treatment group and 9 patients were excluded from the control group). The observation group received Erchen decoction acupoint application in addition to the antiemetic regimen of tropisetron and dexamethasone, while the control group received an acupoint application of pigment powder alongside the same antiemetic regimen as the observation group. The clinical efficacy, pre- and post-treatment grading of nausea and vomiting, adverse reactions, and quality of life scores were compared between the two groups. Results:There was no statistically significant difference in the effective rate of treating vomiting between the two groups ( P > 0.05). However, the total effective rate for delayed vomiting in the observation group was significantly higher at 98.18% (54/55) compared with 84.31% (43/51) in the control group ( χ2 = 4.75, P < 0.05). The proportion of patients in the observation group with a nausea grade of 0 was 76.36% (42/55), which was significantly higher than the 37.25% (19/51) in the control group ( Z = 4.12, P < 0.001). Furthermore, the observation group had higher scores in social functioning [(72.83 ± 6.67)], cognitive functioning [(78.91 ± 5.83)], emotional functioning [(70.65 ± 6.64)], role functioning [(71.70 ± 6.68)], physical functioning [(76.23 ± 7.28)], and overall health [(73.56 ± 6.21)]compared with the control group [(64.57 ± 7.28), (70.87 ± 6.67), (63.24 ± 5.57), (65.36 ± 5.73), (68.82 ± 6.71), and (66.56 ± 5.74), t = 6.10, 6.62, 6.20, 5.23, 5.44, 6.01, all P < 0.05]. There was no statistically significant difference in the incidence of adverse reactions between the two groups ( P > 0.05). Conclusions:Erchen decoction acupoint application can effectively alleviate chemotherapy-induced delayed nausea and vomiting and improve the quality of life of patients.
2.Clinical study on the prevention of chemotherapy-induced nausea and vomiting using Erchen decoction acupoint application
Wanchun YE ; Lingling JIANG ; Ren YE
Chinese Journal of Primary Medicine and Pharmacy 2025;32(11):1640-1644
Objective:To investigate the clinical effects of Erchen decoction acupoint application on the prevention of chemotherapy-induced nausea and vomiting. Methods:A prospective study was conducted involving 120 patients with solid tumors who visited Wenzhou Central Hospital between January 2022 and July 2023. The patients were randomly divided into an observation group and a control group using a random number table method. Ultimately, 55 patients in the observation group and 51 patients in the control group completed the study (due to dropouts or rescue treatment, 5 patients were excluded from the treatment group and 9 patients were excluded from the control group). The observation group received Erchen decoction acupoint application in addition to the antiemetic regimen of tropisetron and dexamethasone, while the control group received an acupoint application of pigment powder alongside the same antiemetic regimen as the observation group. The clinical efficacy, pre- and post-treatment grading of nausea and vomiting, adverse reactions, and quality of life scores were compared between the two groups. Results:There was no statistically significant difference in the effective rate of treating vomiting between the two groups ( P > 0.05). However, the total effective rate for delayed vomiting in the observation group was significantly higher at 98.18% (54/55) compared with 84.31% (43/51) in the control group ( χ2 = 4.75, P < 0.05). The proportion of patients in the observation group with a nausea grade of 0 was 76.36% (42/55), which was significantly higher than the 37.25% (19/51) in the control group ( Z = 4.12, P < 0.001). Furthermore, the observation group had higher scores in social functioning [(72.83 ± 6.67)], cognitive functioning [(78.91 ± 5.83)], emotional functioning [(70.65 ± 6.64)], role functioning [(71.70 ± 6.68)], physical functioning [(76.23 ± 7.28)], and overall health [(73.56 ± 6.21)]compared with the control group [(64.57 ± 7.28), (70.87 ± 6.67), (63.24 ± 5.57), (65.36 ± 5.73), (68.82 ± 6.71), and (66.56 ± 5.74), t = 6.10, 6.62, 6.20, 5.23, 5.44, 6.01, all P < 0.05]. There was no statistically significant difference in the incidence of adverse reactions between the two groups ( P > 0.05). Conclusions:Erchen decoction acupoint application can effectively alleviate chemotherapy-induced delayed nausea and vomiting and improve the quality of life of patients.

Result Analysis
Print
Save
E-mail